Journal of Medicinal Chemistry 2006-06-15

Biological evaluation, chelation, and molecular modeling studies of novel metal-chelating inhibitors of NF-kappaB-DNA binding: structure activity relationships.

Rakesh K Sharma, Shilpa Chopra, Som D Sharma, Vineet Pande, Maria J Ramos, Kazuyuki Meguro, Jun-ichiro Inoue, Masami Otsuka

Index: J. Med. Chem. 49 , 3595-601, (2006)

Full Text: HTML

Abstract

Previously, we have reported that aurintricarboxylic acid (ATA) is one of the most potent inhibitors of the DNA binding of transcription factor NF-kappaB. We now report the NF-kappaB-DNA binding inhibitory activity of ATA analogues. An electrophoretic mobility shift assay has shown that bromopyrogallol red (BPR) is the most effective inhibitor of NF-kappaB-DNA binding among the studied analogues. The molecular modeling studies showed that BPR makes a strong network of hydrogen bonds with the DNA-binding region of the p50 subunit of NF-kappaB and has electronegative potential on its peripheral surface. Because zinc has been reported to influence the DNA binding of NF-kappaB, the interaction of these analogues with zinc was studied. Chemical speciation and formation-constant studies showed that BPR forms the most stable 1:1 complex with zinc. BPR has also been found to be the most potent antioxidant among the studied analogues.


Related Compounds

Related Articles:

Ligand polarizability contributes to tau fibril binding affinity.

2011-09-01

[Bioorg. Med. Chem. 19 , 5147-54, (2011)]

Screening of natural and synthetic drugs against Trypanosoma cruzi. 1. Establishing a structure/activity relationship.

1994-01-01

[Microbios 78(315) , 83-90, (1994)]

Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5.5 and pH 9.0. A pH-induced conformational transition involves a peptide bond flip.

1991-10-05

[J. Mol. Biol. 221(3) , 765-72, (1991)]

Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus.

1986-04-14

[Biochem. Biophys. Res. Commun. 136(1) , 64-71, (1986)]

[Not Available].

1946-09-01

[Ann. Dermatol. Syphiligr. (Paris.) 6(9) , 504, (1946)]

More Articles...